Historically, colorectal cancer treatment has been fairly standard, but this has shifted over the past decade with the introduction of targeted therapies. This week, our focus is on patients with microsatellite instability (dMMR) colorectal cancer, a small but meaningful cohort. This condition affects up to 15% of patients, many of whom carry germline mutations in the MLH1 and MSH2 genes, which simply means that cells can't recognise and fix spontaneous mutations. Historically, these cancers are less responsive to chemotherapy.
This week, we explore two immunotherapy regimens - pembrolizumab, ipilimumab and nivolumab.
Studies discussed in this episode:
For more episodes, resources and blog posts, visit www.inquisitiveonc.com
Please find us on Twitter @InquisitiveOnc!
If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com
Art courtesy of Taryn Silver
Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/
Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.
Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content.
","author_name":"Michael Fernando and Josh Hurwitz"}